Towards Healthcare
Lung Disease Therapeutics Market Size Envisioned at USD 146.1 Billion by 2032

Lung Disease Therapeutics Market Size Envisioned at USD 146.1 Billion by 2032

Status: Published Category: Therapeutic Area Insight Code: 5066 Format: PDF / PPT / Excel

Introduction

  • Research Objective
  • Scope of the Study
  • Definition and Taxonomy

Research Methodology

  • Research Approach
  • Data Sources
  • Assumptions

Executive Summary

  • Synopsis
  • Analyst Recommendations

Market Overview 

  • Market Dynamics
    • Market Drivers
    • Market Restraints
    • Market Opportunities
  • Value Chain Analysis
    • Raw Material Sourcing
    • Manufacturing Process
    • Logistics & Transportation
    • Buyer Preferences
  • Trends
    • Market Trends
    • Technological Trends
  • Porter’s Five Forces Analysis
    • Bargaining Power of Suppliers
    • Bargaining Power of Buyers
    • Threat of Substitute
    • Threat of New Entrants
    • Degree of Competition
  • PESTLE Analysis for 5 Leading Countries
    • Regulatory Framework for Leading Countries/Regions
    • Supply Demand Analysis
    • Production & Consumption Statistics
    • Export Import Statistics
    • Price Trend Analysis

Global Lung Disease Therapeutics Market Assessment

  • Overview
  • Global Lung Disease Therapeutics Market Size Value (US$) and Volume (Billion Tons), by Disease Type (2021 – 2033)
    • Asthma
    • Lung Cancer
    • Chronic Obstructive Pulmonary Disease (COPD)
  • Global Lung Disease Therapeutics Market Size Value (US$) and Volume (Billion Tons), by Drug Class (2021 – 2033)
    • Corticosteroids
    • Bronchodilator
    • Antimicrobial
    • Alkylating Agents
    • Mucolytics
  • Global Lung Disease Therapeutics Market Size Value (US$) and Volume (Billion Tons), by Molecule Type (2021 – 2033)
    • Small molecules
    • Biologics
  • Global Lung Disease Therapeutics Market Size Value (US$) and Volume (Billion Tons), by Treatment Type (2021 – 2033)
    • Chemotherapy
    • Immunotherapy
    • Targeted Therapy
    • Radiation Therapy
  • Global Lung Disease Therapeutics Market Size Value (US$) and Volume (Billion Tons), by Distribution Channel (2021 – 2033)
    • Online
    • Hospital
    • Retail
  • Global Lung Disease Therapeutics Market Size Value (US$) and Volume (Billion Tons), by Geography (2021 – 2033)
    • North America
    • Europe
    • Asia-Pacific
    • Latin America
    • Middle East and Africa

North America Lung Disease Therapeutics Market Assessment

  • Overview
  • North America Lung Disease Therapeutics Market Size Value (US$) and Volume (Billion Tons), by Disease Type (2021 – 2033)
    • Asthma
    • Lung Cancer
    • Chronic Obstructive Pulmonary Disease (COPD)
  • North America Lung Disease Therapeutics Market Size Value (US$) and Volume (Billion Tons), by Drug Class (2021 – 2033)
    • Corticosteroids
    • Bronchodilator
    • Antimicrobial
    • Alkylating Agents
    • Mucolytics
  • North America Lung Disease Therapeutics Market Size Value (US$) and Volume (Billion Tons), by Molecule Type (2021 – 2033)
    • Small molecules
    • Biologics
  • North America Lung Disease Therapeutics Market Size Value (US$) and Volume (Billion Tons), by Treatment Type (2021 – 2033)
    • Chemotherapy
    • Immunotherapy
    • Targeted Therapy
    • Radiation Therapy
  • North America Lung Disease Therapeutics Market Size Value (US$) and Volume (Billion Tons), by Distribution Channel (2021 – 2033)
    • Online
    • Hospital
    • Retail

Europe Lung Disease Therapeutics Market Assessment

  • Overview
  • Europe Lung Disease Therapeutics Market Size Value (US$) and Volume (Billion Tons), by Disease Type (2021 – 2033)
    • Asthma
    • Lung Cancer
    • Chronic Obstructive Pulmonary Disease (COPD)
  • Europe Lung Disease Therapeutics Market Size Value (US$) and Volume (Billion Tons), by Drug Class (2021 – 2033)
    • Corticosteroids
    • Bronchodilator
    • Antimicrobial
    • Alkylating Agents
    • Mucolytics
  • Europe Lung Disease Therapeutics Market Size Value (US$) and Volume (Billion Tons), by Molecule Type (2021 – 2033)
    • Small molecules
    • Biologics
  • Europe Lung Disease Therapeutics Market Size Value (US$) and Volume (Billion Tons), by Treatment Type (2021 – 2033)
    • Chemotherapy
    • Immunotherapy
    • Targeted Therapy
    • Radiation Therapy
  • Europe Lung Disease Therapeutics Market Size Value (US$) and Volume (Billion Tons), by Distribution Channel (2021 – 2033)
    • Online
    • Hospital
    • Retail

Asia-Pacific Lung Disease Therapeutics Market Assessment

  • Overview
  • Asia-Pacific Lung Disease Therapeutics Market Size Value (US$) and Volume (Billion Tons), by Disease Type (2021 – 2033)
    • Asthma
    • Lung Cancer
    • Chronic Obstructive Pulmonary Disease (COPD)
  • Asia-Pacific Lung Disease Therapeutics Market Size Value (US$) and Volume (Billion Tons), by Drug Class (2021 – 2033)
    • Corticosteroids
    • Bronchodilator
    • Antimicrobial
    • Alkylating Agents
    • Mucolytics
  • Asia-Pacific Lung Disease Therapeutics Market Size Value (US$) and Volume (Billion Tons), by Molecule Type (2021 – 2033)
    • Small molecules
    • Biologics
  • Asia-Pacific Lung Disease Therapeutics Market Size Value (US$) and Volume (Billion Tons), by Treatment Type (2021 – 2033)
    • Chemotherapy
    • Immunotherapy
    • Targeted Therapy
    • Radiation Therapy
  • Asia-Pacific Lung Disease Therapeutics Market Size Value (US$) and Volume (Billion Tons), by Distribution Channel (2021 – 2033)
    • Online
    • Hospital
    • Retail

Latin America Lung Disease Therapeutics Market Assessment

  • Overview
  • Latin America Lung Disease Therapeutics Market Size Value (US$) and Volume (Billion Tons), by Disease Type (2021 – 2033)
    • Asthma
    • Lung Cancer
    • Chronic Obstructive Pulmonary Disease (COPD)
  • Latin America Lung Disease Therapeutics Market Size Value (US$) and Volume (Billion Tons), by Drug Class (2021 – 2033)
    • Corticosteroids
    • Bronchodilator
    • Antimicrobial
    • Alkylating Agents
    • Mucolytics
  • Latin America Lung Disease Therapeutics Market Size Value (US$) and Volume (Billion Tons), by Molecule Type (2021 – 2033)
    • Small molecules
    • Biologics
  • Latin America Lung Disease Therapeutics Market Size Value (US$) and Volume (Billion Tons), by Treatment Type (2021 – 2033)
    • Chemotherapy
    • Immunotherapy
    • Targeted Therapy
    • Radiation Therapy
  • Latin America Lung Disease Therapeutics Market Size Value (US$) and Volume (Billion Tons), by Distribution Channel (2021 – 2033)
    • Online
    • Hospital
    • Retail

Middle East and Africa Lung Disease Therapeutics Market Assessment

  • Overview
  • Middle East and Africa Lung Disease Therapeutics Market Size Value (US$) and Volume (Billion Tons), by Disease Type (2021 – 2033)
    • Asthma
    • Lung Cancer
    • Chronic Obstructive Pulmonary Disease (COPD)
  • Middle East and Africa Lung Disease Therapeutics Market Size Value (US$) and Volume (Billion Tons), by Drug Class (2021 – 2033)
    • Corticosteroids
    • Bronchodilator
    • Antimicrobial
    • Alkylating Agents
    • Mucolytics
  • Middle East and Africa Lung Disease Therapeutics Market Size Value (US$) and Volume (Billion Tons), by Molecule Type (2021 – 2033)
    • Small molecules
    • Biologics
  • Middle East and Africa Lung Disease Therapeutics Market Size Value (US$) and Volume (Billion Tons), by Treatment Type (2021 – 2033)
    • Chemotherapy
    • Immunotherapy
    • Targeted Therapy
    • Radiation Therapy
  • Middle East and Africa Lung Disease Therapeutics Market Size Value (US$) and Volume (Billion Tons), by Distribution Channel (2021 – 2033)
    • Online
    • Hospital
    • Retail

Company Profiles

  • Johnson & Johnson
    • Company Overview
    • Geographic Footprints
    • Financial Performance
    • Product Portfolio
    • SWOT Analysis
    • R&D Efforts
    • Recent Developments & Strategic Collaborations
      • Product Launch/M&A/Technical Collaboration
  • Amgen Inc.
  • AstraZeneca
  • Boehringer Ingelheim
  • Pfizer Inc.
  • Allergan Inc.
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • Hoffmann-La Roche
  • Merck & Co
  • Teva Pharmaceutical Industries Ltd.
  • AbbVie, Inc.
  • Novartis AG

Conclusion & Recommendations

  • Insight Code: 5066
  • No. of Pages: 150
  • Format: PDF/PPT/Excel
  • Published: June 2023
  • Report Covered: [Revenue + Volume]
  • Historical Year: 2021-2022
  • Base Year: 2023
  • Estimated Years: 2024-2033

About The Author

Deepa has certified the degree of Master’s in Pharmacy in the Pharmaceutical Quality Assurance department from Dr D.Y. Patil College of Pharmacy. Her research is focused on the healthcare industry. She is the author or co-author of four Review Articles, which include Solid dispersion a strategic method for poorly soluble drugs and solubility improvement techniques for poorly soluble drugs, Herbal Drugs Used In Treatment Of Cataracts, Nano sponges And Their Application in Cancer Prevention and Ayurvedic Remedies of Peptic ulcer. She has also published a Research Article on the Formulation and Evaluation of Mucoadhesive Tablets of Miconazole cocrystal which was published in GIS Science Journal Volume 9 Issue 8. Her passion for secondary research and desire to take on the challenge of solving unresolved issues is making her flourish is the in the research sector.

FAQ's

As of the latest available data, the global lung disease therapeutics market is valued at approximately $81.2 billion in 2022. Please note that market values are subject to change and may vary based on different sources and methodologies used for estimation.

Several factors contribute to the growth of the lung disease therapeutics market, including the increasing prevalence of lung diseases worldwide, rising aging population, growing awareness about respiratory health, technological advancements in diagnostics and treatment options, and the development of targeted therapies. Additionally, lifestyle changes, environmental factors, and the impact of air pollution also play a role in the increasing demand for lung disease therapeutics.

While the growth prospects may vary across different segments, chronic obstructive pulmonary disease (COPD) is expected to witness significant growth in the forecast period. COPD is a leading cause of morbidity and mortality globally, and the rising prevalence of smoking and environmental pollutants contributes to the increasing burden of COPD cases, driving the demand for effective therapeutics.

Warning: include(report-detail-graphs.php): failed to open stream: No such file or directory in /home/thealthcre/public_html/report-toc.php on line 509

Warning: include(): Failed opening 'report-detail-graphs.php' for inclusion (include_path='.:/opt/cpanel/ea-php74/root/usr/share/pear') in /home/thealthcre/public_html/report-toc.php on line 509